By Mauro Orru

Novartis's generics-and-biosimilars division Sandoz was granted marketing authorization from the European Commission to commercialize and distribute Tyruko to treat relapsing forms of multiple sclerosis in the bloc.

The company said Tuesday that Sandoz has the right to commercialize and distribute Tyruko in markets where it is approved through an exclusive agreement with Polpharma Biologics, which makes the treatment. Polpharma Biologics will maintain responsibilities for development of the medicine.

"Today's approval brings us one step closer to reducing the burden of this disease for those living with multiple sclerosis in Europe by making the life-enhancing treatments they need more accessible," said Rebecca Guntern, President for Europe at Sandoz.

Write to Mauro Orru at mauro.orru@wsj.com; @MauroOrru94

(END) Dow Jones Newswires

September 26, 2023 01:48 ET (05:48 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Nov 2023 até Dez 2023 Click aqui para mais gráficos Novartis.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Dez 2022 até Dez 2023 Click aqui para mais gráficos Novartis.